Publications & Insights

Anchoring our work in science and shaping the future of healthcare

Building on more than a decade of research, with a data-driven and technology-based approach, we anchor our solutions in scientific discoveries and evidence. We are committed to the highest level of quality and integrity when bringing life-saving knowledge and solutions to the benefit of patients.

30
Scientific studies featuring LiverPRO, including own and external research
.
80
ROC-AUC for LiverPRO in detecting significant liver fibrosis1
.
80
Harrell’s C for LiverPRO in predicting liver-related outcomes1*
1Lindvig, K. P., et al. (2025). The Lancet Gastroenterology & Hepatology. DOI:10.1016/S2468-1253(24)00274-7
*Claim not covered by the CE-certification of LiverPRO.

Publications

XX
Show all publications

Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study

Lindvig, K. P., et al.
Original research
January 2025
The Lancet Gastroenterology & Hepatology

LiverPRO reduces false positives and screening costs compared with Fibrosis-4 Index in steatotic liver disease

Thorhauge, K. H., et al.
Original research
January 2026
Clinical Gastroenterology & Hepatology

Prevalence of fibrosis and applicability of lab-based noninvasive tests from primary to tertiary care

Semmler, G., et al.
Original research
September 2025
Clinical Gastroenterology & Hepatology

Steatotic liver disease trajectory: a holistic EASL guidance on the multidisciplinary approach to screening and patient management

Pieter, B. W., et al.
Review
February 2026
JHEP Reports

Fibrosis progression rate and comparison of paired liver biopsy vs noninvasive tests as surrogate endpoints for clinical trials in Metabolic and Alcohol-Associated Liver Disease and Alcohol-Associated Liver Disease

Jensen, E. L., et al.
Original research
Clinical Gastroenterology & Hepatology

LiverPRO can optimize trial recruitment and lower screen failure rates in steatotic liver disease (Poster ID: 2016)

Astono, J., et al.
Original research
November 2025
The Liver Meeting 2025
Show all publications

Insights

XX
Show all insights

Risk assessment

Lehman-Becker, L. (Roche Diagnostics)
Opinion pieces
September 2026

Prevent-Stop-Cure: Diagnostics and chronic liver disease

Lehman-Becker, L. (Roche Diagnostics) & Raleigh, N. (Pharmaphorum)
Podcast episodes
August 2026

Algorithms for better diagnostics are gaining ground in hepatology

Lindvig, K. P., Thiele, M., & Krag, A.
Expert pieces
September 2024

Data-driven healthcare solutions are key to future care

Holtug, T.
Opinion pieces
June 2024

The price tag of a hidden global liver pandemic

Lindvig, K. P., Holtug, T., Krag, A., & Thiele, M.
White papers
August 2023

How to end the global liver pandemic?

Holtug, T., Lindvig, K. P., Krag, A., & Thiele, M.
White papers
January 2023
Show all insights

News

XX
Show all news

LiverPRO is available on the navify® Algorithm Suite from Roche

External
May 27, 2026

Maja Thiele joins Evido Health as CSO and Katrine Prier Lindvig is appointed CMO

Evido Health
January 28, 2026

Aleksander Krag, Scientific Co-founder, receives award for breakthroughs in early detection of chronic liver disease

External
January 27, 2026

Kristian Villumsen joins as Chair of Evido Health

Evido Health
December 11, 2025

Former Coloplast CEO becomes chair of Danish HealthTech company Evido Health

External
December 11, 2025

Evido Health receives Arvind Hundal Scale-Up Award at NOME annual meeting

Evido Health
November 18, 2025
Show all news
Would you like to learn more?

Gain a better understanding of how our technology and solutions can be used and scaled in your practice, supporting you in detecting patients with liver fibrosis early and accurately.

Let’s get the conversation and collaboration going.

Book a demo